Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 227Carcinoma, Non-Small-Cell Lung 220Prostatic Neoplasms 156Multiple Myeloma 142Neoplasms 134Colorectal Neoplasms 118Leukemia, Myeloid, Acute 109Lung Neoplasms 103Neoplasm Metastasis 99Squamous Cell Carcinoma of Head and Neck 93Carcinoma, Hepatocellular 85Lymphoma 80Melanoma 77Pancreatic Neoplasms 73Triple Negative Breast Neoplasms 72Ovarian Neoplasms 71Sarcoma 66Lymphoma, Large B-Cell, Diffuse 62Recurrence 61Head and Neck Neoplasms 60Carcinoma, Renal Cell 59Brain Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Lymphoma, Non-Hodgkin 54Endometrial Neoplasms 54Leukemia, Lymphocytic, Chronic, B-Cell 53Hematologic Neoplasms 53Stomach Neoplasms 52Small Cell Lung Carcinoma 50Urinary Bladder Neoplasms 47

Interventions

trifluridine tipiracil drug combination 1Nivolumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Microsatellite-stable Colorectal Cancer × 90 days × Clear all
NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Suspended
7 enrolled
Gastrointestinal

Microsatellite-stable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡